Market Closed -
Nasdaq Stockholm
11:29:47 2024-05-15 EDT
|
5-day change
|
1st Jan Change
|
1.785
SEK
|
+0.28%
|
|
0.00%
|
-42.60%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
154.8
|
342.2
|
224.7
|
257
|
193.1
|
110.8
|
-
|
Enterprise Value (EV)
1 |
154.8
|
342.2
|
183
|
257
|
164
|
68.33
|
110.8
|
P/E ratio
|
-3.04
x
|
-4.79
x
|
-2.89
x
|
-3.51
x
|
-
|
5.95
x
|
-1.62
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1,847,089
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
1,847,089
x
|
EV / EBITDA
|
-
|
-
|
-2.37
x
|
-
|
-4.34
x
|
-1.47
x
|
-15.8
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
53.6
x
|
4.02
x
|
-1.71
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
1.86%
|
24.9%
|
-58.7%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
37,766
|
37,766
|
37,766
|
62,087
|
62,087
|
62,087
|
-
|
Reference price
2 |
4.100
|
9.060
|
5.950
|
4.140
|
3.110
|
1.785
|
1.785
|
Announcement Date
|
20-02-28
|
21-02-26
|
22-02-24
|
23-02-24
|
24-02-27
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
0.00006
|
EBITDA
1 |
-
|
-
|
-77.35
|
-
|
-37.79
|
-46.5
|
-7
|
EBIT
1 |
-
|
-
|
-77.93
|
-
|
-38.26
|
-46.5
|
-7
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
Earnings before Tax (EBT)
1 |
-
|
-
|
-77.78
|
-
|
-37.17
|
-46.5
|
-7
|
Net income
1 |
-50.86
|
-71.37
|
-77.78
|
-56.24
|
-37.17
|
-46.5
|
-7
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-11,666,666.67%
|
EPS
2 |
-1.350
|
-1.890
|
-2.060
|
-1.180
|
-
|
0.3000
|
-1.100
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.057
|
17
|
-65
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-108,333,333.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-28
|
21-02-26
|
22-02-24
|
23-02-24
|
24-02-27
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
41.7
|
-
|
29.1
|
42.5
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
3.06
|
17
|
-65
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.05
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-28
|
21-02-26
|
22-02-24
|
23-02-24
|
24-02-27
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| -42.60% | 10.37M | | +7.52% | 113B | | +11.38% | 106B | | -12.64% | 22.22B | | +0.44% | 22.27B | | -4.18% | 19.43B | | -37.85% | 17.87B | | -8.58% | 17.24B | | +37.41% | 12.52B | | -23.95% | 8.34B |
Bio Therapeutic Drugs
|